agan
Long

DRREDDY in BUY mode

NSE:DRREDDY   DR REDDYS LABS
22 0 0
Fundamentally a STRONG company and it had recent news for its upmove

Dr             Reddy's Laboratories has expanded strategic collaboration with Amgen             , one of the world's leading independent biotechnology companies, to market and distribute three of Amgen's medicines             in India in the therapy areas of oncology and osteoporosis. Under the terms of the collaboration, the company will commercialise XGEVA'(denosumab), Vectibix' (panitumumab) and Prolia (donosumab) in India.

The BSE             group 'A' stock of face value Rs             . 5 has touched a 52 week high of Rs             . 4382.95 on 20-Oct-2015 and a 52 week low of Rs             . 2750.00 on 21-Jan-2016.

The promoters holding in the company stood at 26.37%, while institutions and non-institutions held 41.16% and 15.64% respectively.

Dr             . Reddy’s Laboratories has been listed as an Index component of the Dow Jones Sustainability Indices (DJSI) 2016 in the Pharmaceuticals, Biotechnology & Life Sciences Industry Group. The pharma             major has been recognized for its corporate sustainability leadership and is the only pharmaceutical company on the Index of Emerging Markets.
The listing was based on 22 criterion, with Dr             . Reddy’s receiving high scores for Product Quality and Recall Management, Codes of Business Conduct, Environmental Reporting, Corporate Citizenship and Philanthropy.
United States
United Kingdom
India
Deutschland
France
España
Italia
Polska
Türkiye
Россия
Brasil
Indonesia
Malaysia
ประเทศไทย
Việt Nam
日本
한국
简体
繁體
Home Stock Screener Forex Signal Finder Cryptocurrency Signal Finder Economic Calendar How It Works Chart Features House Rules Moderators Website & Broker Solutions Widgets Stock Charting Library Feature Request Blog & News FAQ Help & Wiki Twitter
Profile Profile Settings Account and Billing My Support Tickets Contact Support Ideas Published Followers Following Private Messages Chat Sign Out